Clostridium difficile

Microorganisms grown from a researcher’s hand are being used in an art contest.

Researchers are beginning to uncover a link between activity level and the microbial makeup of one’s gut.

Ribaxamase significantly reduced Clostridium difficile infection in a mid-stage clinical trial involving more than 400 patients.

Contrary to the popular thought that many species are “unculturable,” the majority of bacteria known to populate the human gut can be grown in the lab, scientists show.

Researchers build a mathematical model that can predict whether a mouse will be infected by Clostridium difficile based on the microbes found in its GI tract.

Gut microbiome analysis reveals protective bacteria that enhance resistance to persistent Clostridium difficile infections.

A long-term study confirms transplants of stool microbes from healthy donors can successfully clear recurrent Clostridium difficile infections.

A study shows that fecal transplants in an oral capsule form are an effective treatment for Clostridium difficile infection.

Oral administration of a cocktail of bacteria derived from the human gut reduces colitis and allergy-invoked diarrhea in mice.

From now on, US physicians and researchers will have to get approval from the FDA before they can perform a stool transplant.

Fecal transplants outcompeted traditional antibiotics at curing a deadly intestinal infection.

Transplanting synthetic stool made of beneficial microbes cures deadly diarrheal infections in two patients.

Mice fed a mix of six strains of bacteria were able to fight a C. difficile infection that causes deadly diarrhea and is resistant to most types of treatment.